The boom of Viagra initially fueled significant expansion in the pharmaceutical sector, producing a image of easy gains. However, investing in companies solely reliant on flagship drugs like Sildenafil presents substantial risks. Intellectual property end has led alternative competition, eroding market share and likely decreasing projected earni… Read More

The recent surge in capital into specialized pharmaceutical companies, particularly those focusing on experimental therapies and difficult drug development programs, has fueled what some are calling "High Roller Pharma." While the potential for revolutionary treatments and impressive returns is undeniable, the linked risks are also notable. Many… Read More